The Complete Guide to Semaglutide: Ozempic and Wegovy Explained

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Most Ozempic side effects are short-term, improving over time or when stopping the medication, with symptoms often improving after 3 months.
Ozempic has been studied in clinical trials for up to 41 months for adults with type 2 diabetes and chronic kidney disease.
Wegovy is designed to be started at a low dose and increased slowly to help the body adjust and reduce side effects.
Possible serious side effects for Wegovy include thyroid tumors, including cancer, as observed in studies with rodents.

Semaglutide medications like Ozempic and Wegovy have become important tools for managing type 2 diabetes and for weight loss. Ozempic, a semaglutide medication, received approval from the U.S. Food and Drug Administration (FDA) primarily to help individuals with Type 2 diabetes regulate their blood sugar levels. This regulatory effect can also contribute to weight loss. Similarly, Wegovy is another semaglutide medication specifically designed for weight management. While both medications offer significant benefits, understanding their potential side effects, both common and long-term, is crucial for anyone considering or currently using them. Most side effects of Ozempic are short-term and tend to resolve with time or if the medication is stopped. For example, many people find that their Ozempic side effects improve after about 3 months of use. However, there are also potential long-term issues that could persist for months or even years after discontinuing the drug, such as pancreatitis, vision problems, kidney injury, and skin changes. Clinical trials have investigated Ozempic for varying durations, including 30 weeks for type 2 diabetes, 104 weeks for cardiovascular outcomes in SUSTAIN trials, and up to 41 months in adults with type 2 diabetes and chronic kidney disease, providing a detailed picture of its effects.

What are Semaglutide Medications Like Ozempic and Wegovy?

Semaglutide medications like Ozempic and Wegovy are part of a class of drugs known as GLP-1 receptor agonists. These medications work by mimicking a natural hormone in the body called glucagon-like peptide-1 (GLP-1), which plays a key role in regulating blood sugar and appetite. Ozempic, specifically, is an FDA-approved semaglutide medication that is primarily prescribed for people living with Type 2 diabetes. Its main function in this context is to help control blood sugar levels. Beyond its primary use for diabetes, Ozempic's effects on appetite and digestion can also lead to weight loss. Wegovy, on the other hand, is another formulation of semaglutide, but it is specifically approved for chronic weight management in adults. Both medications are administered as injections, though an oral form of semaglutide (Rybelsus) also exists.

How Semaglutide Works in the Body

Semaglutide works by binding to GLP-1 receptors in the body. When it activates these receptors, it triggers several beneficial actions. First, it stimulates the pancreas to release more insulin when blood sugar levels are high, which helps lower blood glucose. Second, it reduces the amount of glucagon released by the pancreas, which prevents the liver from releasing too much sugar into the bloodstream. Third, semaglutide slows down gastric emptying, meaning food stays in the stomach longer. This can lead to a feeling of fullness and reduced appetite, which is a major factor in its effectiveness for weight loss. This slowed digestion can also contribute to some of the common gastrointestinal side effects.

Key Differences Between Ozempic and Wegovy

While both Ozempic and Wegovy contain the active ingredient semaglutide, their approved uses and typical dosing schedules differ. Ozempic is primarily indicated for improving blood sugar control in adults with type 2 diabetes and for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. The maximum dose for weight management with Wegovy is typically higher than the doses used for diabetes management with Ozempic. Despite their different primary indications, both medications have shown effects on both blood sugar and weight.

Important Safety Considerations for Semaglutide

It is important to understand that both Ozempic and Wegovy may cause serious side effects. One significant concern across both medications is the potential for thyroid tumors, including cancer. Studies conducted with rodents showed that Wegovy and other medicines that work like Wegovy caused thyroid tumors, including thyroid cancer. While this finding is from animal studies, it is not currently known if Wegovy will cause thyroid tumors or a specific type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Due to this potential risk, healthcare providers advise patients to be vigilant. Patients should immediately inform their healthcare provider if they notice a lump or swelling in their neck, experience hoarseness, have trouble swallowing, or feel shortness of breath. These symptoms could indicate thyroid cancer. Furthermore, individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Wegovy. This strict contraindication highlights the serious nature of this potential side effect.

What are the Common Short-Term Side Effects of Ozempic?

Most side effects experienced with Ozempic are generally mild to moderate and often improve over time as the body adjusts to the medication. These symptoms are most likely to occur when someone first starts taking Ozempic or after their dose is increased. For many individuals, these common side effects tend to subside, with Ozempic side effects after 3 months often showing significant improvement. This adjustment period is a normal part of starting a new medication that impacts the digestive system and metabolism.

Gastrointestinal Discomfort

The most commonly reported side effects of Ozempic largely involve the gastrointestinal system. Users may experience a range of symptoms, including abdominal pain or discomfort. This pain can vary in intensity and location. Loss of appetite is also frequently reported, which contributes to the medication's weight loss effects but can sometimes be excessive. Indigestion or heartburn are other common complaints, indicating that the digestive process is being affected. Nausea and vomiting are also very common, particularly when initiating treatment or increasing the dose. These symptoms can be disruptive but usually lessen as the body adapts to the medication.

Injection Site Reactions

Since Ozempic is administered via injection, some individuals may experience reactions at the injection site. These reactions are typically mild and localized. Common injection site reactions include redness, swelling, or itching around where the injection was given. These symptoms are usually temporary and do not indicate a more serious problem. Proper injection technique and rotating injection sites can help minimize these occurrences. It is important to remember that these are localized responses and not usually indicative of a systemic allergic reaction unless accompanied by other severe symptoms.

Managing Common Side Effects

Managing these common side effects often involves strategies to help the body adjust. Starting with a low dose and gradually increasing it, as is common practice with semaglutide medications like Wegovy, can help reduce the severity of initial side effects. Eating smaller, more frequent meals, avoiding fatty or spicy foods, and staying well-hydrated can also help alleviate gastrointestinal symptoms. For injection site reactions, applying a cool compress can provide relief. Patients are encouraged to discuss persistent or bothersome side effects with their healthcare provider, who may suggest adjustments to the dosing schedule or prescribe medications to help manage symptoms like nausea. The temporary nature of most of these side effects means that many people can successfully continue their treatment as their body adapts.

Duration of Side Effects

The duration of these common side effects varies from person to person. As previously noted, many individuals find that their Ozempic side effects improve after about 3 months of consistent use. This timeframe aligns with the body's natural adaptation process to new medications. However, some people might experience symptoms for a shorter period, while for others, they might linger slightly longer. It is also important to note that these symptoms are most pronounced when first starting Ozempic or after a dose increase. Once a stable dose is reached and the body has adjusted, the frequency and intensity of these side effects typically decrease. If side effects remain severe or do not improve, it is always best to consult a healthcare professional.

Can Ozempic Cause Long-Term Side Effects?

Yes, Ozempic has been associated with certain long-term side effects that may persist for months or even years after a person stops taking the medication. While most side effects are short-term and resolve, some potential problems can have a lasting impact. These include serious conditions like pancreatitis, various vision problems, kidney injury, and even changes in skin appearance, sometimes referred to as 'Ozempic face'. The possibility of such prolonged issues makes it critical for users and healthcare providers to monitor for symptoms throughout treatment and even after discontinuation.

Clinical Trial Insights into Long-Term Effects

Clinical trials have provided valuable data on the long-term safety profile of Ozempic. The medication was studied for 30 weeks in trials focused on type 2 diabetes. For cardiovascular outcomes, the SUSTAIN trials extended over 104 weeks. Furthermore, Ozempic was investigated for an even longer duration, 41 months, in adults with type 2 diabetes and chronic kidney disease. These extensive study periods allow researchers to identify effects that might not appear in shorter trials. These studies contribute to our understanding of both the efficacy and the potential long-term risks associated with the medication. Rare but serious long-term effects that have been identified can include gallbladder problems and a potential risk of thyroid tumors, underscoring the need for comprehensive safety monitoring.

Pancreatitis Risk

Pancreatitis, which is an inflammation of the pancreas, has been reported by some individuals who took Ozempic during clinical trials. However, a direct causal link between Ozempic and pancreatitis remains unclear. In one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis, compared to 10 people taking a placebo, suggesting that the incidence was not higher with the drug. Similarly, in pooled studies of oral semaglutide (Rybelsus/Ozempic tablet), 6 people reported pancreatitis compared to 1 in the comparator group. More recently, a comprehensive meta-analysis involving approximately 35,000 patients concluded that semaglutide is not associated with a higher risk of pancreatitis when compared to placebo. Despite these findings, cases of pancreatitis continue to be reported in patients using the medication, emphasizing the importance of recognizing its symptoms, which include severe upper stomach pain that may radiate to the back, nausea or vomiting, and a rapid heartbeat. Pancreatitis usually resolves within two weeks, but there was one reported case of chronic (long-term) pancreatitis in a patient during clinical trials.

Vision Problems

Ozempic may also contribute to or worsen certain eye conditions. One notable concern is the potential to exacerbate diabetic retinopathy, an eye condition common in people with diabetes, particularly when blood sugar levels improve rapidly. In a 2-year study, 3% of Ozempic injection users experienced complications related to diabetic retinopathy, compared to 1.8% of those taking a placebo. In pooled placebo and active-controlled trials, 4.2% of oral semaglutide (Rybelsus/Ozempic tablet) users reported diabetic retinopathy, compared to 3.8% in the comparator group. Beyond diabetic retinopathy, Ozempic might also cause a condition known as non-arteritic anterior ischemic optic neuropathy (NAION). This condition occurs when the optic nerve does not receive enough blood supply, which can lead to vision loss. These vision-related side effects highlight the need for regular eye examinations for individuals on Ozempic, especially those with pre-existing diabetes.

Other Long-Term Concerns

Beyond pancreatitis and vision issues, other long-term effects have been noted. Kidney injury and changes in kidney function have been reported. Rapid weight loss associated with Ozempic can also lead to noticeable body composition changes, often described as "Ozempic face" or "Ozempic body," where fat loss in the face or other areas can alter appearance. The product liability attorneys at Sullivan Papain Block McManus Coffinas & Cannavo P.C. explore the potential dangers of Ozempic and the complications it may cause and discuss some of the severe long-term effects users have reported. This perspective underscores the seriousness with which these long-term effects are viewed, prompting legal and medical attention.

What are the Risks of Pancreatitis and Vision Problems with Ozempic?

While Ozempic offers significant benefits for managing type 2 diabetes and aiding weight loss, it carries specific risks related to pancreatitis and various vision problems. Pancreatitis, an inflammation of the pancreas, has been reported by some individuals taking Ozempic, although a definitive causal link remains unclear. Rapid improvements in blood sugar levels can also sometimes worsen existing eye conditions like diabetic retinopathy.

Understanding Pancreatitis and Ozempic

Pancreatitis is a serious condition that can cause severe upper stomach pain, often radiating to the back, along with nausea, vomiting, and a rapid heartbeat. Although rare, cases of pancreatitis have been noted in people using Ozempic. For example, in one 2-year study, 8 people receiving injectable Ozempic developed pancreatitis, which was actually fewer than the 10 people in the placebo group who experienced the condition. In studies that combined data from oral semaglutide (Rybelsus/Ozempic tablet), 6 individuals reported pancreatitis compared to 1 in the group not taking the medication. Despite these observations, a more recent meta-analysis that included about 35,000 patients found that semaglutide is not associated with a higher risk of pancreatitis compared to placebo. This suggests that while individual cases occur, the overall risk may not be elevated. However, given the potential severity of pancreatitis, it is crucial for patients to be aware of its signs and symptoms and to seek immediate medical attention if they suspect they are experiencing it. Pancreatitis typically resolves within two weeks, but there has been at least one report of chronic pancreatitis in a patient during Ozempic clinical trials.

Ozempic and Diabetic Retinopathy

Diabetic retinopathy is an eye condition that can lead to vision impairment or blindness and is common among individuals with diabetes. Ozempic may worsen this condition, particularly when blood sugar levels improve very quickly. This rapid change can sometimes stress the delicate blood vessels in the eyes, leading to complications. In a 2-year study, 3% of Ozempic injection users experienced complications related to diabetic retinopathy, compared to 1.8% of those taking a placebo. This difference, though seemingly small, indicates a potential increased risk. Similarly, in pooled placebo and active-controlled trials, 4.2% of oral semaglutide (Rybelsus/Ozempic tablet) users reported diabetic retinopathy, compared to 3.8% in the comparator group. Regular eye examinations are highly recommended for all individuals with diabetes, and especially for those starting or taking Ozempic, to monitor for any changes or worsening of diabetic retinopathy.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Beyond diabetic retinopathy, Ozempic might also be linked to another serious eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION). NAION occurs when the optic nerve, which transmits visual information from the eye to the brain, does not receive an adequate blood supply. This lack of blood flow can cause sudden, painless vision loss in one eye. While rare, this condition represents a significant concern for vision health. Patients experiencing any sudden changes in vision while on Ozempic should consult their healthcare provider immediately. The potential for these vision problems underscores the importance of a thorough discussion of all risks and benefits with a healthcare professional before starting Ozempic. The information regarding potential complications and long-term effects of Ozempic is crucial for informed decision-making. Potential complications of Ozempic for weight loss should be carefully reviewed by all users.

How Does Ozempic Affect the Digestive System and Other Organs?

Ozempic significantly impacts the digestive system, leading to both common and, in rare cases, severe complications. While many experience mild gastrointestinal issues, the medication's mechanism of slowing digestion can also pose risks to other organs, including the kidneys, and affect overall metabolic balance, potentially leading to low blood sugar.

Gastrointestinal Issues: From Common to Severe

Gastrointestinal issues are among the most commonly reported side effects of Ozempic. These include nausea, vomiting, diarrhea, or abdominal pain. These symptoms are a direct result of semaglutide's action of slowing gastric emptying, which makes food stay in the stomach for a longer period. While often mild and temporary, these symptoms can sometimes be severe enough to lead to dehydration or malnutrition if not managed properly. Patients experiencing persistent or severe gastrointestinal distress should seek medical advice to prevent these complications.

In rare instances, Ozempic can cause more serious gastrointestinal complications. These include gastroparesis, often referred to as "stomach paralysis," where the stomach's muscles don't function properly to move food through the digestive tract. Another rare but serious complication is intestinal blockage. Both gastroparesis and intestinal blockage can lead to significant discomfort, vomiting, and a need for medical intervention. These rare but serious long-term Ozempic side effects can include pancreatitis, gallbladder problems, kidney issues, vision changes, and a risk of thyroid tumors, as outlined in detailed safety information. Ozempic side effects and clinical trials provide extensive data on these observations.

Hypoglycemia Risk

Ozempic's primary function in individuals with type 2 diabetes is to lower blood sugar levels. While beneficial for diabetes management, this effect can lead to hypoglycemia, or low blood sugar, if not closely monitored. Symptoms of hypoglycemia can include dizziness, confusion, sweating, tremors, hunger, and a rapid heartbeat. In severe cases, hypoglycemia can result in fainting or even seizures. This risk is particularly concerning for individuals without diabetes who use Ozempic solely for weight loss, as their bodies may not be accustomed to such significant blood sugar reductions. Close monitoring of blood sugar and understanding the symptoms of hypoglycemia are vital for all Ozempic users.

Kidney Damage and Function Loss

Ozempic has been associated with kidney issues. While it may help protect heart and kidney health in people with type 2 diabetes or obesity, some reports indicate kidney damage and loss of kidney function as potential long-term effects. This can range from worsening of pre-existing kidney conditions to new onset kidney injury. It is important for individuals with kidney disease or those at risk for kidney problems to have their kidney function closely monitored while taking Ozempic. The interplay between blood sugar control, blood pressure, and kidney health is complex, and any new medication can shift this balance.

Gallbladder Disease and Complications

Gallbladder disease and related complications are another potential long-term issue associated with Ozempic. These can include gallstones, which may lead to severe abdominal pain, nausea, and vomiting. In some cases, gallbladder inflammation (cholecystitis) may occur, requiring medical intervention, possibly even surgery. While these complications are considered rare, they are important to be aware of, especially for individuals with a history of gallbladder problems or those experiencing new onset symptoms. Any severe pain in the upper right abdomen should be promptly reported to a healthcare provider.

What are the Dangers of Thyroid Tumors and Other Serious Conditions?

The potential for thyroid tumors, including cancer, represents one of the most serious warnings associated with semaglutide medications like Wegovy. This risk, observed in animal studies, necessitates careful consideration and vigilant monitoring for human users. Beyond thyroid concerns, these medications can also lead to other severe and rare conditions that demand immediate medical attention.

Thyroid Tumor Risk: Insights from Rodent Studies

A critical piece of safety information for Wegovy and other medicines that work like it, such as Ozempic, comes from studies conducted with rodents. In these animal studies, semaglutide caused thyroid tumors, including thyroid cancer. Specifically, a type of thyroid cancer called medullary thyroid carcinoma (MTC) was observed. It is important to clarify that while these findings are significant in animal models, it is not yet known if Wegovy will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people. This uncertainty means that while a direct link in humans hasn't been definitively established, the potential risk is serious enough to warrant strong warnings and precautions.

Identifying Symptoms of Thyroid Cancer

Due to the potential risk identified in animal studies, individuals taking Wegovy must be aware of the symptoms that could indicate thyroid cancer. Patients should immediately tell their healthcare provider if they experience any of the following: a lump or swelling in the neck, hoarseness in their voice, trouble swallowing, or shortness of breath. These symptoms may be subtle at first but can be crucial indicators of thyroid cancer. Early detection is vital for successful treatment of any cancer, making patient awareness and prompt reporting essential for those on semaglutide medications.

Contraindications for Wegovy Use

Given the serious nature of the potential thyroid tumor risk, specific contraindications exist for Wegovy. Individuals should not use Wegovy if they or any of their family members have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). This family history suggests a genetic predisposition that could increase risk. Furthermore, Wegovy is contraindicated for those with an endocrine system condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is a genetic disorder that causes tumors in multiple endocrine glands, including the thyroid, and significantly increases the risk of MTC. These strict guidelines are in place to protect individuals who may be at a higher inherent risk for developing thyroid cancer. Understanding this important safety information is paramount for any potential user. Wegovy important safety information provides a comprehensive overview of these critical warnings.

Other Serious but Rare Conditions

Beyond thyroid tumors, other serious but rare conditions associated with semaglutide medications include the aforementioned pancreatitis and gallbladder disease. Pancreatitis, an inflammation of the pancreas, can be life-threatening and involves severe abdominal pain and digestive issues. While a meta-analysis of about 35,000 patients suggested no higher risk of pancreatitis with semaglutide compared to placebo, individual cases have been reported, making vigilance crucial. Gallbladder problems, such as gallstones, can also arise, leading to pain and potentially requiring medical intervention. Mental health effects are also listed as potential long-term issues, though specific details are often less clear in general summaries. These severe side effects, though infrequent, highlight the importance of ongoing communication with healthcare providers and prompt reporting of any concerning symptoms while on semaglutide treatment.

How is Wegovy Dosed for Weight Loss?

Wegovy (semaglutide) is specifically designed for chronic weight management and follows a carefully structured dosing schedule. The approach emphasizes starting with a very low dose and gradually increasing it over several weeks. This gradual titration is a key strategy to help the body adjust to the medication, which in turn can significantly reduce the likelihood and severity of side effects, particularly common gastrointestinal symptoms like nausea.

The Importance of Gradual Titration

The practice of "starting low and increasing slowly" is fundamental to the Wegovy dosing protocol. This method allows the body ample time to adapt to the presence of semaglutide. If the dose were to be increased too quickly, the sudden impact on the digestive system and appetite regulation could lead to more intense and disruptive side effects. By slowly stepping up the dose, individuals are more likely to tolerate the medication, adhere to their treatment plan, and ultimately achieve better weight loss outcomes. As stated by PandaMeds.com, "Wegovy® (semaglutide) is designed to be started low and increased slowly. Gradual titration helps your body adjust, which can reduce the likelihood that side effects (especially nausea and other GI symptoms) disrupt treatment." This expert consensus underscores the critical role of this dosing strategy.

The Step-by-Step Dosing Schedule

The typical Wegovy dosing schedule for weight loss progresses through several increments, starting at a very low dose and gradually increasing until a maintenance dose is reached. The schedule usually begins with a 0.25mg weekly injection. This initial dose is maintained for approximately four weeks to allow for initial adaptation. Following this, the dose is typically increased to 0.5mg weekly for another four weeks. This pattern continues with progressive increases to 1.0mg, 1.7mg, and finally to the full maintenance dose of 2.4mg weekly. Each dose increase is typically maintained for a month before moving to the next level. This structured approach helps manage the body's response to the medication. The complete schedule for Wegovy can be found in a detailed guide, often progressing from 0.25mg to 2.4mg. Wegovy Dosing Guide 2026: 0.25mg to 2.4mg Schedule | Step-by-Step provides an example of such a comprehensive guide.

Managing Side Effects During Dose Increases

Even with gradual titration, some individuals may still experience side effects, especially during dose increases. The most common side effects during this period are gastrointestinal, such as nausea, vomiting, diarrhea, and constipation. To help manage these symptoms, healthcare providers often recommend strategies such as eating smaller, more frequent meals, staying well-hydrated, and avoiding rich or fatty foods. If side effects become too bothersome or severe at a particular dose, a healthcare provider might suggest staying at that dose for a longer period before increasing, or in some cases, temporarily reducing the dose. The goal is to find the highest tolerated and effective dose while minimizing discomfort.

Long-Term Adherence and Monitoring

Adherence to the weekly Wegovy schedule is crucial for its effectiveness in weight management. Patients typically self-administer the medication using a pre-filled pen. It is important to follow the instructions provided by the healthcare provider and the medication's packaging carefully. Regular follow-up appointments with a healthcare provider are essential to monitor progress, assess for side effects, and make any necessary adjustments to the treatment plan. This ongoing support ensures that individuals receive the full benefits of Wegovy while minimizing potential risks. The Wegovy dosing schedule for weight loss is a step-by-step guide designed to maximize efficacy and minimize side effects. Wegovy Dosing Schedule for Weight Loss: Step-by-Step Guide explains this process.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy both contain the active ingredient semaglutide, but they are approved for different primary uses. Ozempic is primarily prescribed for adults with Type 2 diabetes to improve blood sugar control and reduce cardiovascular risk. Wegovy, on the other hand, is specifically approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition. While both can lead to weight loss, their approved indications and typical maximum dosages differ, with Wegovy generally prescribed at higher doses for weight loss.

How long do Ozempic side effects usually last?

Most common side effects of Ozempic, such as nausea, abdominal pain, and loss of appetite, are typically short-term. They often improve over time as your body adjusts to the medication, or they resolve completely if you stop taking it. For many people, these symptoms significantly improve after about 3 months of consistent use. However, some long-term side effects like pancreatitis or vision problems, though rare, could potentially last for months or even years.

Can Ozempic cause permanent damage to organs?

While rare, Ozempic has been associated with some serious long-term side effects that could potentially lead to organ damage. These include pancreatitis, which can be severe, and kidney injury or loss of kidney function. There's also a potential, though not yet confirmed in humans, risk of thyroid tumors, including cancer, observed in rodent studies. For example, in one 2-year study, 3% of Ozempic injection users experienced complications related to diabetic retinopathy. It is crucial to monitor for any severe symptoms and discuss them promptly with a healthcare provider to mitigate risks.

Is it safe to use Ozempic for weight loss if I don't have diabetes?

Ozempic is not FDA-approved for weight loss in individuals without type 2 diabetes. While it can cause weight loss, its use for this purpose in non-diabetic individuals is off-label. Using Ozempic without diabetes carries specific risks, such as hypoglycemia (low blood sugar), which can lead to dizziness, confusion, or even seizures if not closely monitored. The approved semaglutide medication for weight loss in individuals without diabetes (or with diabetes but for weight management) is Wegovy.

What should I do if I experience severe side effects from Ozempic or Wegovy?

If you experience severe side effects from Ozempic or Wegovy, you should contact your healthcare provider immediately. Severe symptoms could include intense abdominal pain that radiates to your back (pancreatitis), severe vomiting or diarrhea leading to dehydration, sudden vision changes, or symptoms like a lump in your neck or trouble swallowing. For example, in one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis. Your provider can assess your condition, recommend appropriate actions, and determine if your medication dosage needs adjustment or if the medication should be stopped.